Filing Analysis
Delisting Notice
Filed Mar 11, 2026
HIGH
VYNE Therapeutics has been granted a 180-day extension by Nasdaq to regain compliance with the $1.00 minimum bid price requirement, extending the deadline to September 7, 2026. The company failed to meet the requirement during the initial 180-day period and is now explicitly considering a reverse stock split as a potential remedy.
Red Flags
- Failure to regain compliance within the first 180-day window
- Explicit mention of a potential reverse stock split to cure the deficiency
- Prolonged period (over 6 months) of the stock trading below the $1.00 threshold
Key Facts
- Received Nasdaq extension notice on March 11, 2026
- New compliance deadline is September 7, 2026
- Initial deficiency notice was received on September 12, 2025
- Company must maintain a closing bid price of at least $1.00 for 10 consecutive business days to regain compliance
- Nasdaq granted the extension based on the company meeting all other continued listing requirements
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.